TRIUMEQ PD Drug Patent Profile

Which patents cover Triumeq Pd, and when can generic versions of Triumeq Pd launch?

Triumeq Pd is a drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-seven patent family members in thirty-five countries.

The generic ingredient in TRIUMEQ PD is abacavir sulfate; dolutegravir sodium; lamivudine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; dolutegravir sodium; lamivudine profile page.

DrugPatentWatch^® Generic Entry Outlook for Triumeq Pd

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2030. This may change due to patent challenges or generic licensing.

There have been twenty-five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRIUMEQ PD

International Patents:	157
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIUMEQ PD

Paragraph IV (Patent) Challenges for TRIUMEQ PD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIUMEQ PD	Tablets for Oral Suspension	abacavir sulfate; dolutegravir sodium; lamivudine	60 mg/5 mg/30 mg	215413	1	2023-03-31

US Patents and Regulatory Information for TRIUMEQ PD

TRIUMEQ PD is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 9,242,986.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes	9,242,986*PED				Y
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes	8,129,385*PED				Y
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes

International Patents for TRIUMEQ PD

When does loss-of-exclusivity occur for TRIUMEQ PD?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Japan

Mexico

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIUMEQ PD around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E516026
Australia	2006239177	Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Australia	2006307101	Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
Brazil	PI0610030	composto, processo para a preparação de um composto, método de tratamento de uma infecção por hiv em um humano, uso de um composto, e, composição farmacêutica
Brazil	PI0617842	composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
Canada	2606282	DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASEINHIBITORY ACTIVITY)
Canada	2626956	DERIVE DE CARBAMOYLPYRIDONE POLYCYCLIQUE AYANT UNE ACTIVITE D'INHIBITION SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE)

Supplementary Protection Certificates for TRIUMEQ PD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2465580	132021000000098	Italy		PRODUCT NAME: CABOTEGRAVIR(VOCABRIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1481, 20201221
1874117	C201430032	Spain		PRODUCT NAME: DOLUTEGRAVIR O UNA SAL O SOLVATO DEL MISMO FARMACEUTICAMENTE ACEPTABLE, INCLUIDA LA SAL SODICA DE DOLUTEGRAVIR.; NATIONAL AUTHORISATION NUMBER: EU/1/13/892; DATE OF AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/892; DATE OF FIRST AUTHORISATION IN EEA: 20140116
2465580	2021C/519	Belgium		PRODUCT NAME: VOCABRIA-CABOTEGRAVIR; AUTHORISATION NUMBER AND DATE: EU/1/20/1481 20201221
1874117	202 50006-2014	Slovakia		PRODUCT NAME: SODNA SOL DOLUTEGRAVIRU; REGISTRATION NO/DATE: EU/1/13/892/001 - EU/1/13/892/002 20140121
2465580	C202130021	Spain		PRODUCT NAME: CABOTEGRAVIR; NATIONAL AUTHORISATION NUMBER: EU/1/20/1481; DATE OF AUTHORISATION: 20201217; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1481; DATE OF FIRST AUTHORISATION IN EEA: 20201217
1874117	122014000066	Germany		PRODUCT NAME: DOLUTEGRAVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON, EINSCHLIESSLICH DOLUTEGRAVIRNATRIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140116
2465580	301109	Netherlands		PRODUCT NAME: CABOTEGRAVIR; REGISTRATION NO/DATE: EU/1/20/1481 20201217

Last updated: July 16, 2026

TRIUMEQ PD (abacavir/dolutegravir/lamivudine) Investment Scenario, Patent Estate, and FDA/Commercial Fundamentals

TRIUMEQ PD is the pediatric “powder for oral suspension” line of TRIUMEQ (abacavir + dolutegravir + lamivudine) targeting HIV-1 treatment in children. The investment case hinges on (1) pediatric label breadth and dosing adoption, (2) durability of IP/exclusivity around the pediatric product and any optimized pediatric formulations, (3) whether multiple ANDA and/or 505(b)(2) routes emerge as exclusivities expire, and (4) payer and clinic switching risk away from current pediatric regimens.

---

What is TRIUMEQ PD and what HIV populations does it cover?

TRIUMEQ PD is a pediatric dosage form of a fixed-dose three-drug antiretroviral combination:

• Abacavir (NRTI)
• Dolutegravir (INSTI)
• Lamivudine (NRTI)

It is positioned for children living with HIV-1 who require a weight-appropriate pediatric formulation and dosing flexibility.

Pediatric use case and switching friction

Pediatric HIV therapy creates stickiness because:

• Dosing is weight- and age-dependent, and liquid formulations are often required to avoid under- or over-dosing.
• Clinicians and pharmacists maintain stable regimens to limit adherence disruption during growth changes.
• Pediatric regimen changes drive operational cost (new dosing schedules, formulation handling, monitoring workflows).

The investment implication: TRIUMEQ PD can sustain revenue when it becomes embedded into pediatric formularies and standard-of-care pathways, even if adult TRIUMEQ faces competitive pressures.

---

How does TRIUMEQ PD compare with pediatric alternatives for first-line HIV?

Investment-grade comparisons usually segment by formulation class and “clinic fit”:

INSTI-based triple therapy competition

The main category competition is INSTI-based triple therapy with pediatric-appropriate formulations, including:

• Abacavir/lamivudine backbones paired with dolutegravir or other INSTIs
• Alternative fixed-dose combinations that use pediatric film-coated tablets, dispersible tablets, or suspensions

Key differentiators for TRIUMEQ PD are:

• A single-product, three-drug regimen that simplifies regimen complexity
• A pediatric oral suspension format that supports dosing by weight

Where competition most affects pricing power

Commercial pressure accelerates when:

• Multiple pediatric-formulation options land on formularies
• Payers impose step therapy or narrow preferred INSTI options
• Wholesale acquisition cost (WAC) discounts materially shift net price

---

What patents protect TRIUMEQ PD and related pediatric formulations?

For a pediatric version, the risk and upside can come from three different IP buckets:

1. Composition-of-matter covering abacavir/dolutegravir/lamivudine
2. Fixed-dose combination coverage and manufacturing/solid-state/process protections
3. Pediatric-specific protections (formulation, particle size, dissolution profile, excipients, stability, packaging)

How to interpret the patent estate for TRIUMEQ PD

For investors, the patent estate’s commercial relevance comes from “barrier to generic/pediatric entry”:

• If patents on the core combination are still in force, ANDA-style entry is blocked regardless of pediatric-formulation changes.
• If core combo patents have expired but pediatric-specific patents remain, generic entrants can face delay unless they design around the formulation claims or prevail in litigation.

Patent-lifecycle questions that drive valuation

• Are there formulation patents unique to the oral suspension presentation?
• Are there method-of-treatment patents tied to pediatric dosing or weight-based regimens?
• Are there secondary patents on manufacturing scale, granulation, milling, or stabilization?

(Concrete patent numbers and expiration dates are required for precision, but no Orange Book/patent list data was provided in the prompt, and producing it from memory risks false specificity.)

---

When does TRIUMEQ lose exclusivity for pediatric use?

Exclusivity analysis for a pediatric dosage form should be done in parallel:

• Patent expiration dates (primary and formulation patents)
• Regulatory exclusivities (data exclusivity, pediatric exclusivity if applicable)
• Trademark and market exclusivity only where they affect access (less common as a primary driver in generics)

Featured-snippet answer

TRIUMEQ PD’s exclusivity timeline is determined by the last expiring relevant patent covering the pediatric dosage form and any tied pediatric regulatory exclusivity attached to the pediatric label.

A precise date requires the Orange Book listing and any associated patent term extensions for:

• the pediatric suspension product code
• each listed NDA reference product for the combination

Those data are not included in the input.

---

What generic entry risks exist for TRIUMEQ PD after exclusivity expires?

The generic-entry risk depends on whether an abbreviated pathway is feasible:

• ANDA is possible for small molecules if the product is substitutable and meets sameness standards.
• 505(b)(2) can be used when literature or bridging studies are needed.

For a pediatric suspension, the key barriers are:

• formulation similarity (dissolution, stability, bioavailability)
• manufacturing equivalence and scale-up reproducibility
• whether formulation patents are asserted or still in force

Likely entry strategy for challengers

Generic sponsors typically pursue:

• fast-follow pediatric liquid offerings if patents allow design-around
• bioequivalence bridging packages to reduce clinical burden
• manufacturing location diversification to reduce supply disruption risk

Investment takeaway

The valuation upside is highest when:

• TRIUMEQ PD is protected by multiple layers of formulation/manufacturing patents
• pediatric label breadth is broad enough to limit “partial replacement” strategies

---

What patent litigation affects TRIUMEQ PD or its TRIUMEQ backbone?

Patent litigation is a primary near-term driver for:

• settlement amounts and take-or-pay licensing
• entry-date stay outcomes
• market-entry timing for authorized generics or licensees

How litigation impacts investment timing

Even when patents expire, litigation can:

• delay launches via injunctions
• delay approval via USPTO and Hatch-Waxman process outcomes
• create authorized generic arrangements with delayed entry

A precise litigation timeline requires case numbers, forum (Delaware/SDNY, etc.), and asserted patents. None were provided in the prompt.

---

What is the Orange Book status of TRIUMEQ PD?

Orange Book status is the core dataset for:

• patent listing completeness
• which patents are tied to the pediatric NDA supplement or product-specific listing
• whether any unexpired patents remain at the time of entry evaluation

A correct answer requires the product’s Orange Book listing (NDA number, application type, dosage form, and all listed patents).

No Orange Book listing identifiers (NDA/BLA and product code) were provided, so this cannot be stated accurately.

---

How strong is the patent estate for TRIUMEQ PD versus peer pediatric HIV products?

In pediatric INSTI combinations, a “strong estate” usually means:

• multiple independent claims on formulation and manufacturing
• continuing coverage of critical quality attributes (dissolution/stability)
• downstream protections on pediatric dosing regimens where legally anchored

A “weak estate” usually means:

• only early combination coverage remains (simple structure and substitution risk)
• limited formulation coverage
• fewer barriers to AB-rating substitution after core patent expiry

Quantifying “strength” for investment models

A typical model scores:

• number of listed patents by category (composition, formulation, method, process)
• remaining term at key forecast dates
• probability of settlement or litigation outcomes
• design-around feasibility

Without the actual patent listing, the scoring cannot be completed without fabricating data.

---

What formulations are protected by TRIUMEQ PD patents?

For pediatric suspension products, formulation protection tends to cover:

• excipient system and buffering conditions
• particle size and polymorph control
• stabilization against hydrolysis/oxidation
• dissolution profile and oral bioavailability consistency
• shelf-life and packaging compatibility

Investment relevance: if formulation patents exist, generics can be blocked even after core drug patents expire by challenging validity or designing around the claimed formulation parameters.

No formulation patent details were provided in the prompt.

---

What method-of-use patents are relevant to TRIUMEQ PD?

Method-of-use risk typically arises when:

• patents claim specific pediatric dosing strategies
• patents claim clinical outcomes in pediatric populations
• patents claim weight-based regimen schedules or monitoring steps

If no method-of-use patents exist, generic sponsors focus on formulation and bioequivalence.

No method-of-use patents were provided in the input.

---

Which companies are likely competing with TRIUMEQ PD in pediatrics?

Competitors in pediatric INSTI-based HIV therapy generally include:

• originator rivals with pediatric INSTI combinations
• generic entrants once barriers lift
• specialty brands with pediatric liquid or dispersible offerings

A precise competitor list for TRIUMEQ PD requires the most current pediatric HIV formulary landscape and pipeline review tied to the exact product’s label.

No competitor list data was provided.

---

What is the regulatory status of TRIUMEQ PD (FDA pathway, label scope, pediatric approvals)?

Regulatory status drives:

• time-to-market for generics (label breadth and reference product specificity)
• whether label updates create patent term adjustments or exclusivity triggers
• whether pediatric waivers or deferred pediatric studies affect competition timing

A correct regulatory summary requires:

• NDA number and supplement number(s)
• label indication and pediatric age range
• approval dates for initial and supplemental approval(s)

Those specifics were not included in the prompt.

---

What is the commercial revenue exposure for TRIUMEQ PD under realistic substitution scenarios?

A fundamentals model for TRIUMEQ PD should be built on three revenue drivers:

1. pediatric population penetration (treated children on INSTI regimens)
2. formulary share and net price (rebates/discounts)
3. substitution timing (when generics or alternative pediatric formulations gain access)

Scenario framework investors use

• Base case: TRIUMEQ PD maintains pediatric share with periodic downward pressure on net price
• Competition case: formulation alternatives gain preferred status as contracts renew
• Patent cliff case: exclusivity expires and generics enter the pediatric suspension market quickly

A quantitative scenario requires TRIUMEQ PD-specific sales, net price history, and market share by pediatric age band. None were provided.

---

Key Takeaways

• TRIUMEQ PD is a pediatric oral suspension fixed-dose antiretroviral combination (abacavir/dolutegravir/lamivudine). The investment thesis is anchored to pediatric label stickiness and formulation adoption.
• The main valuation swing factor is IP durability at the pediatric-dosage-form and combination levels, plus whether any Orange Book-listed patents block abbreviated entry.
• Competitive and generic-entry timing depends on the specific patent listing, regulatory exclusivities, and whether formulation and manufacturing protections exist for the suspension presentation.
• A fully decision-grade investment model requires: Orange Book patent list for TRIUMEQ PD, the remaining term for each listed patent (including pediatric-relevant formulation patents), FDA label scope, and any litigation affecting entry.

---

FAQs

1) What drives pricing and rebate pressure for pediatric HIV fixed-dose combinations like TRIUMEQ PD?
Net price is primarily driven by payer contracting mechanics (rebates/AMP-based dynamics), formulary position, and whether competing pediatric suspensions or preferred INSTI backbones gain “preferred” status at plan renewal.

2) How do formulation patents for an oral suspension change generic entry timelines?
Formulation patents can force challengers to litigate or redesign around claimed composition, particle size, dissolution, or stabilization features, delaying approval or launch even if core drug patents expire.

3) Can a generic launch rely on bioequivalence alone for a pediatric suspension?
If the product is blocked by unexpired listed patents, bioequivalence cannot override legal barriers; absent patent protection, generic sponsors still must meet sameness and pediatric formulation performance requirements.

4) What role does pediatric label breadth play in protecting TRIUMEQ PD revenue?
Broader pediatric dosing coverage increases treatment lock-in and makes partial substitution harder, reducing revenue erosion from class-level competitors.

5) What litigation outcomes most impact investor forecasts for HIV combinations?
Settlements that grant authorized entry dates, outcomes that invalidate key formulation patents, and stays/injunctions that alter launch timing are the biggest near-term forecast drivers.

---

References (APA)

1. (No citable source data was provided in the prompt.)